Search

Displaying results 1071 - 1080 of 10000 in total
  1. Target

    Short transient receptor potential channel 4

    go.drugbank.com/bio_entities/BE0020751
    TargetHumans

    Forms a receptor-activated non-selective calcium permeant cation channel (PubMed:11042129, PubMed:11713258, PubMed:16144838, PubMed:39478185).

    Polypeptides: Short transient receptor potential channel 4
  2. Target

    Short transient receptor potential channel 5

    go.drugbank.com/bio_entities/BE0021113
    TargetHumans

    Forms a receptor-activated non-selective calcium permeant cation channel (PubMed:16284075, PubMed:38959890, PubMed:37137991).

    Polypeptides: Short transient receptor potential channel 5Synonyms: Transient receptor protein 5
  3. Target

    Taste receptor type 2 member 14

    go.drugbank.com/bio_entities/BE0023216
    TargetHumans

    Gustducin-linked G protein-coupled receptor that plays a role in the perception of bitterness (PubMed:38600377, PubMed:38776963). … The activity of this receptor stimulates GNAT3, activating the gustducin G protein pathway (PubMed:38600377, PubMed:38776963).

    Polypeptides: Taste receptor type 2 member 14Synonyms: Taste receptor family B member 1
  4. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use. … Vanoxerine is a highly selective dopamine transporter antagonist. It was synthesized in the late 1970s and developed as a potential treatment for depression.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 1-(2-(bis(p-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine
  5. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. … [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023.

    Categories: Orexin Receptor Antagonists, Cytochrome P-450 Substrates
  6. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … It possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.

    Categories: MATE 1 Inhibitors, P-glycoprotein inhibitors
  7. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain.

  8. Indication

    Anticholinergic Syndrome

    go.drugbank.com/conditions/DBCOND0005987
    Drugs: Physostigmine
    Synonyms: Poisoning caused by acetylcholine receptor antagonist, Poisoning caused by acetylcholine receptor antagonist (disorder)
  9. Drug

    Brilliant green cation

    go.drugbank.com/drugs/DB11279
    ApprovedVet approved

    Brilliant green, or ethanaminium, is a derivative of triarylmethane dye that has been used as a dye to color silk and wool. … Due to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.

    Synonyms: Brilliant green(1+), Brilliant green ionSalts: Brilliant green
  10. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). … [L47036,L47057,L4274,L4278] A further study is required to verify and describe the clinical benefits of Galafold, and the sponsor will be conducting a confirmatory clinical trial of Galafold in adults

    Categories: Alpha-Galactosidase A (alpha-Gal A) Pharmacological Chaperones, Heterocyclic Compounds, 1-RingSynonyms: 1-Deoxygalactostatin, 1-Deoxygalactonojirimycin